BRIEF published on 03/20/2026 at 13:05, 1 month 26 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 1 month 26 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 1 month 26 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 7 months 16 days ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF published on 09/30/2025 at 07:05, 7 months 16 days ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE published on 09/30/2025 at 07:00, 7 months 16 days ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 10 months 15 days ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
BRIEF published on 07/01/2025 at 07:05, 10 months 15 days ago ReproNovo lance un essai de phase 2 pour un médicament contre l'infertilité masculine aux États-Unis Essai De Phase 2 ReproNovo RPN-001 Infertilité Masculine Faible Taux De Testostérone
PRESS RELEASE published on 07/01/2025 at 07:00, 10 months 15 days ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
BRIEF published on 05/21/2025 at 07:05, 11 months 26 days ago ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health Innovation Clinical Trials Series A Financing Reproductive Health ReproNovo
Published on 05/16/2026 at 01:15, 9 hours 8 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 10 hours 23 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 11 hours 13 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 11 hours 23 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/15/2026 at 20:10, 14 hours 13 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 16 hours 13 minutes ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 17:33, 16 hours 50 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 05/15/2026 at 15:08, 19 hours 15 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 19 hours 23 minutes ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 1 day ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 2 days 1 hour ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 16 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
